Shots: The P-III SUNRISE 1 (Study 304) study involves assessing of DAYVIGO (lemborexant, 5 or 10 mg) vs an active comparator or PBO in 1,006 patients with insomnia disorder aged […]readmore
Tags : Lemborexant
Shots: The approval is based on two P-III studies (study 1 & 2) assessing Dayvigo (5mg/10mg, once nightly) vs PBO in patients aged ≥18yrs. & in female patients aged ≥55yrs. […]readmore
Shots: Purdue to receive one-time payment from Eisai, while releasing itself from rights to develop & commercialize lemborexant. Eisai acquires WW development and commercialization rights for lemborexant, previously held by […]readmore
Shots: The P-III SUNRISE 2 study involves assessing of Lemborexant (5mg,10mg) vs PBO in 949 patients with insomnia disorder, characterized by difficulty in falling asleep/staying asleep aged 18 to 88yrs. […]readmore